$488.64
0.67% today
Nasdaq, Sep 16, 08:14 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$485.37
+17.78 3.80% 1M
+72.17 17.47% 6M
+78.48 19.29% YTD
+138.53 39.94% 1Y
+294.65 154.49% 3Y
+310.43 177.45% 5Y
+393.24 426.83% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+6.72 1.40%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $125.27b
Enterprise Value $120.41b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.66
P/S ratio (TTM) P/S ratio 12.14
P/B ratio (TTM) P/B ratio 8.48
Revenue growth (TTM) Revenue growth 10.32%
Revenue (TTM) Revenue $10.32b
EBIT (operating result TTM) EBIT $-391.00m
Free Cash Flow (TTM) Free Cash Flow $-1.18b
Cash position $5.80b
EPS (TTM) EPS $-2.03
P/E forward negative
P/S forward 11.64
EV/Sales forward 11.18
Short interest 1.70%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

21x Buy
60%
11x Hold
31%
3x Sell
9%

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
60%
Hold
31%
Sell
9%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
9,839 9,839
12% 12%
100%
- Direct Costs 1,262 1,262
17% 17%
13%
8,577 8,577
12% 12%
87%
- Selling and Administrative Expenses 955 955
20% 20%
10%
- Research and Development Expense 3,163 3,163
20% 20%
32%
4,459 4,459
5% 5%
45%
- Depreciation and Amortization 181 181
22% 22%
2%
EBIT (Operating Income) EBIT 4,277 4,277
5% 5%
43%
Net Profit 3,620 3,620
9% 9%
37%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Seeking Alpha
one day ago
Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos and potentially more powerful than NSAIDs and ibuprofen in post-surgery pain relief. VX-548 appears to fill the therapeutic gap between NSAIDs and opioids.
Positive
The Motley Fool
2 days ago
AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.
Positive
The Motley Fool
2 days ago
One of these stocks stands to benefit from interest rate cuts that could be on the way. Another will soon launch a new product that could become its most successful ever.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 5,400
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today